Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth O Hexner

Showing results (81-90 of 105) with videos related to

Pageof 11
Sort By:
Blood Advances|December 22, 2020
Biomarker-guided preemption of steroid-refractory graft-versus-host disease with α-1-antitrypsinStephanie C Gergoudis, Zachariah DeFilipp, Umut Özbek, et al.
Nature Medicine|September 27, 2024
Cytokine-mediated CAR T therapy resistance in AMLAnand S Bhagwat, Leonel Torres, Olga Shestova, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2021
Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults With Relapsed or Refractory Acute Lymphoblastic LeukemiaRegina M Myers, Yimei Li, Allison Barz Leahy, et al.
JCI Insight|February 15, 2017
An early-biomarker algorithm predicts lethal graft-versus-host disease and survivalMatthew J Hartwell, Umut Özbek, Ernst Holler, et al.
Nature Medicine|March 14, 2024
Intrathecal bivalent CAR T cells targeting EGFR and IL13Rα2 in recurrent glioblastoma: phase 1 trial interim resultsStephen J Bagley, Meghan Logun, Joseph A Fraietta, et al.
Cell Reports. Medicine|August 19, 2025
Clinical and molecular dissection of CAR T cell resistance in pancreatic cancerM Angela Aznar, Charly R Good, Julie S Barber-Rotenberg, et al.
Transplantation and Cellular Therapy|September 2, 2024
Differences in Acute Graft-Versus-Host Disease (GVHD) Severity and Its Outcomes Between Black and White PatientsCarlos A Ortega Rios, Muna Qayed, Aaron M Etra, et al.
Leukemia|February 6, 2020
Disease risk and GVHD biomarkers can stratify patients for risk of relapse and nonrelapse mortality post hematopoietic cell transplantMina D Aziz, Jay Shah, Urvi Kapoor, et al.
JCI Insight|August 24, 2018
An early-biomarker algorithm predicts lethal graft-versus-host disease and survivalMatthew J Hartwell, Umut Özbek, Ernst Holler, et al.
Blood|July 5, 2024
Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHDYu Akahoshi, Nikolaos Spyrou, Daniela Weber, et al.
Pageof 11

Showing results (81-90 of 105) with videos related to

Sort By:
Pageof 11
Blood Advances|December 22, 2020
Biomarker-guided preemption of steroid-refractory graft-versus-host disease with α-1-antitrypsinStephanie C Gergoudis, Zachariah DeFilipp, Umut Özbek, et al.
Nature Medicine|September 27, 2024
Cytokine-mediated CAR T therapy resistance in AMLAnand S Bhagwat, Leonel Torres, Olga Shestova, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2021
Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults With Relapsed or Refractory Acute Lymphoblastic LeukemiaRegina M Myers, Yimei Li, Allison Barz Leahy, et al.
JCI Insight|February 15, 2017
An early-biomarker algorithm predicts lethal graft-versus-host disease and survivalMatthew J Hartwell, Umut Özbek, Ernst Holler, et al.
Nature Medicine|March 14, 2024
Intrathecal bivalent CAR T cells targeting EGFR and IL13Rα2 in recurrent glioblastoma: phase 1 trial interim resultsStephen J Bagley, Meghan Logun, Joseph A Fraietta, et al.
Cell Reports. Medicine|August 19, 2025
Clinical and molecular dissection of CAR T cell resistance in pancreatic cancerM Angela Aznar, Charly R Good, Julie S Barber-Rotenberg, et al.
Transplantation and Cellular Therapy|September 2, 2024
Differences in Acute Graft-Versus-Host Disease (GVHD) Severity and Its Outcomes Between Black and White PatientsCarlos A Ortega Rios, Muna Qayed, Aaron M Etra, et al.
Leukemia|February 6, 2020
Disease risk and GVHD biomarkers can stratify patients for risk of relapse and nonrelapse mortality post hematopoietic cell transplantMina D Aziz, Jay Shah, Urvi Kapoor, et al.
JCI Insight|August 24, 2018
An early-biomarker algorithm predicts lethal graft-versus-host disease and survivalMatthew J Hartwell, Umut Özbek, Ernst Holler, et al.
Blood|July 5, 2024
Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHDYu Akahoshi, Nikolaos Spyrou, Daniela Weber, et al.
Pageof 11